| Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. | |
| | |
MedLine Citation:
|
PMID: 20382637 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles. METHODS: The subjects were post-menopausal Japanese patients who had undergone surgery for early breast cancer. Toremifene or tamoxifen was administered for 2 years. Lipid levels were measured before and up to 24 months after initiation. RESULTS: Compared with baseline, at 24 months, the toremifene group (n = 123) showed significantly decreased total cholesterol (P < 0.001) and low-density lipoprotein cholesterol levels (P < 0.001), and significantly increased high-density lipoprotein cholesterol levels (P < 0.001). Their triglyceride levels were not affected (P = 0.677). The tamoxifen group (n = 120) also showed significantly decreased total cholesterol (P < 0.001) and low-density lipoprotein cholesterol levels (P < 0.001); no significant changes occurred in high-density lipoprotein cholesterol (P = 0.297) or triglyceride levels (P = 0.120). CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation. |
| | |
Authors:
|
Takeshi Tominaga; Izo Kimijima; Morihiko Kimura; Yuichi Takatsuka; Shigemitsu Takashima; Yasuo Nomura; Fujio Kasumi; Akihiro Yamaguchi; Norikazu Masuda; Shinzaburo Noguchi; Nobuoki Eshima |
Related Documents
:
|
8612407 - Low lipid concentrations in critical illness: implications for preventing and treating ... 6405907 - Hypocholesterolaemia and non-cardiovascular disease: metabolic studies on subjects with... 10928647 - Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory. 9158437 - Weight-independent cardiovascular fitness and coronary risk factors. 10197567 - Risk of persistent cobalamin deficiency in adolescents fed a macrobiotic diet in early ... 11689017 - Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome p4502e1. |
Publication Detail:
|
Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-04-08 |
Journal Detail:
|
Title: Japanese journal of clinical oncology Volume: 40 ISSN: 1465-3621 ISO Abbreviation: Jpn. J. Clin. Oncol. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-30 Completed Date: 2010-07-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0313225 Medline TA: Jpn J Clin Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 627-33 Citation Subset: IM |
Affiliation:
|
Breast Cancer Center, Toyosu Hospital, Showa University, Tokyo, Japan. t-tominaga@hkg.odn.ne.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents, Hormonal / therapeutic use* Breast Neoplasms / blood, drug therapy* Chemotherapy, Adjuvant Female Humans Japan Lipids / blood* Middle Aged Postmenopause Tamoxifen / therapeutic use* Toremifene / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Hormonal; 0/Lipids; 10540-29-1/Tamoxifen; 89778-26-7/Toremifene |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic Impact of Vascular Endothelial Growth Factor-A and E-Cadherin Expression in Completely Re...
Next Document: Interpreting Tuberculin Skin Tests in a Population With a High Prevalence of HIV, Tuberculosis, and ...